Impact of Vitamin D Status on Pancreatic Cancer Risk and Outcomes

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Vitamin D (VD) is a prohormone with known roles in cell growth, differentiation, and immune responses.
• Emerging evidence suggests a connection between Vitamin D and pancreatic ductal adenocarcinoma (PDAC) biology.
• VD deficiency is common in PDAC patients, correlating with inflammation and poorer survival.

Purpose of the Study:

• To review the current evidence on Vitamin D's role in pancreatic ductal adenocarcinoma (PDAC).
• To explore mechanistic, epidemiological, and clinical aspects of VD in PDAC.
• To identify knowledge gaps and the need for further clinical trials.

Main Methods:

• This study is a narrative review.
• It synthesizes existing experimental, epidemiological, and clinical data on Vitamin D and PDAC.
• Emphasis is placed on current limitations and future research directions.

Main Results:

• Experimental studies indicate VD can inhibit PDAC cell growth and modify the tumor microenvironment.
• Epidemiological data show a link between VD deficiency, inflammation, and reduced survival in PDAC patients.
• Meta-analyses present inconsistent findings regarding VD levels and PDAC incidence, though higher levels may correlate with better survival.

Conclusions:

• The precise role and clinical utility of Vitamin D supplementation in PDAC prevention and treatment remain unclear.
• Further well-designed clinical trials are necessary to establish optimal dosing, timing, and patient selection for VD therapy.
• Clarifying the therapeutic and prognostic significance of Vitamin D in pancreatic cancer is crucial.